HCM - ハチソン・チャイナ・メディテック （Hutchison China MediTech Limited）

U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) shares fell 10.6% to $4.18. Atea Pharmaceuticals'' board unanimously rejected unsolicited proposal from Tang Capital Partners'' Affiliate, Concentra Biosciences. HUTCHMED (China) Limited (NASDAQ: HCM ) shares tumbled 9.9% to $12.06. Sana Biotechnology, Inc. (NASDAQ: SANA ) fell 9% to $5.72. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) … Full story available on Benzinga.com

ALLISTON, ON , May 29, 2023 /CNW/ - Honda of Canada Mfg. (HCM) today celebrated a milestone achievement in automotive manufacturing in Canada , celebrating the building of the 10 millionth vehicle to come off the production lines in Alliston, Ontario , a 2023 Honda CR-V Touring Hybrid. It was 1986 when Honda became the first Japanese automobile manufacturer to establish a production facility in Canada . Since then, HCM has been home to iconic Honda models like the Accord, Odyssey, Pilot and Ridgeline and Acura EL, CSX and ZDX vehicles. The three HCM plants currently build Honda CR-Vs, Civics and four-cylinder engines. "This achievement is a testament to the hard work, commitment and dedication of generations of HCM associates, I want to thank and congratulate them on this historic milestone," said Jean Marc Leclerc , President and CEO Honda Canada. "Since 1986, HCM has been a class leader in Canadian automotive manufacturing and production and one of Honda''s most important facilities on a global scale.

Takeda and HUTCHMED Limited today announced that the U.S. Food and Drug Administration has granted priority review of the New Drug Application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer. The post Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review [Business Wire India] appeared first on Insurance News | InsuranceNewsNet .

Shanghai, China & Hong Kong & Osaka, Japan & Cambridge, Mass., Florham Park, N.J., United States: − Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 30, 2023 − NDA Includes Results From the Phase 3 FRESCO-2 and FRESCO Clinical Trials Takeda (TSE:4502/NYSE:TAK) and HUTCHMED […] The post Takeda and HUTCHMED Announce New Drug Application NDA for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review appeared first on Businessfortnight .

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapies fruquintinib, surufatinib and HMPL-453 in 21 abstracts that will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL and online.

Bullfrog AI (BFRG) +16%. HUTCHMED (China) (HCM) +10%. Scilex (SCLX) -17%. Allarity Therapeutics (ALLR) -13%.

… patients with non-small cell lung cancer (NSCLC) with MET exon 14 …

Hutchmed (China) (HCM) said it consulted China''s drug regulator to start registration phase enrollments in cancer trials. Read more here

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reached an agreement to initiate the registration phase of the ongoing Phase II trial of HMPL-453 for intrahepatic cholangiocarcinoma (“IHCC”) patients with fibroblast growth factor receptors (“FGFR”) 2 fusion. If positive, the data from the registration phase may be used to support a future New Drug Application (“NDA”) filing. The first patient received their first dose in March 2023.

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China —

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China —

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Silicon Valley Bank UK Limited (“SVBUK”). The Company does not hold any cash deposits or securities with SVB or SVBUK.

HUTCHMED (China) Limited (NASDAQ:NASDAQ:HCM) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ETCompany ParticipantsMark Lee - SVP Corporate Finance and Development Weiguo Su -…

Hutchison China MediTech press release (HCM): FY GAAP EPADS of -$2.13 misses by $0.02.Revenue of $426.4M (+19.7% Y/Y) beats by $16.62M.Cash, Cash Equivalents and Short-Term…

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib in patients with relapsed or refractory follicular lymphoma (“FL”), a subtype of non-Hodgkin’s lymphoma (“NHL”). The last patient was enrolled on February 24, 2023.